Ursodeoxycholic Acid IR Pellets are pharmaceutical-grade immediate-release multiparticulate pellets containing Ursodeoxycholic Acid (UDCA) as the active pharmaceutical ingredient. They are designed for oral formulation applications where rapid availability of the active ingredient from individual pellet units is required.
Ursodeoxycholic Acid, also known as Ursodiol, is identified by CAS Number 128-13-2, molecular formula C₂₄H₄₀O₄, and molecular weight 392.66 g/mol. These chemical identity parameters are established in current chemical reference data.
Commercial pharmaceutical pellet portfolios specifically document Ursodeoxycholic Acid IR Pellets at 35% w/w, while another commercial pellet reference documents a substantially higher 76.50% w/w IR format. A published formulation example has also demonstrated UDCA pellets containing 50% or 69% UDCA depending on the formulation design. These differences demonstrate that finished-pellet loading is formulation-specific rather than a universal property of the active ingredient.
For the SDP website, the available strength should therefore be stated according to the current SDP product specification or COA.
Ursodeoxycholic Acid is a bile acid with limited water solubility, making formulation design, particle characteristics, active distribution and dissolution performance important considerations during development. An immediate-release pellet system can provide a flexible multiparticulate platform in which active loading, pellet size, excipient composition and physical characteristics can be optimized for the intended oral formulation.
Ursodeoxycholic Acid Immediate-Release Pellets are developed as multiple individual pellet units rather than a single-unit formulation. This multiparticulate structure provides flexibility during formulation development and can support controlled processing during downstream capsule-filling operations.
The performance of an immediate-release pellet system can depend on the composition of the pellet core, UDCA loading, pellet size, excipient selection, porosity, surface characteristics and manufacturing process. Published UDCA pellet formulations demonstrate the use of excipients such as starch, HPMC, crospovidone, microcrystalline cellulose and other formulation components to produce pellet systems through processes such as extrusion and spheronization.
The exact formulation composition and manufacturing parameters should be established according to the applicable finished-product specification rather than assumed from another commercial or published formulation.
Commercial references demonstrate that Ursodeoxycholic Acid IR Pellets can be manufactured across different active-loading levels. One established commercial pellet portfolio lists 35% w/w, while another lists 76.50% w/w for an IR pellet format.
For the SDP website:
Available Strength: [Insert current SDP-confirmed strength]
The active loading should only be published after confirmation against the current SDP product specification or COA.
Active loading is an important characteristic because it determines the amount of Ursodeoxycholic Acid present within a defined quantity of pellets. It can also influence pellet composition, excipient ratio, physical properties, processing requirements and dissolution performance.
The multiparticulate structure of Ursodeoxycholic Acid IR Pellets provides formulation flexibility for oral pharmaceutical applications. Each pellet functions as an individual unit within the formulation, allowing developers to evaluate active distribution, particle characteristics and release performance.
Ursodeoxycholic Acid IR Pellets can be considered for:
The final suitability depends on the formulation design, manufacturing process and applicable finished-product requirements.
Capsule filling is an important application of pharmaceutical multiparticulate pellets. Ursodeoxycholic Acid IR Pellets can be developed with suitable particle-size distribution, density, flow characteristics and mechanical strength to support capsule-filling operations.
Consistent pellet characteristics can help support reproducible filling and active distribution. Important physical parameters may include:
The appropriate physical specifications should be established according to the intended formulation and finished-product requirements.
The release performance of Ursodeoxycholic Acid IR Pellets depends on the formulation and manufacturing design. Important variables can include:
Published UDCA multiparticulate formulations demonstrate that pellet composition and processing can be adjusted to achieve an immediate-release formulation. One published formulation reported more than 80% active release within 30 minutes, while another formulation reported more than 75% release within 60 minutes. These are specific formulation examples, not universal dissolution specifications for all Ursodeoxycholic Acid IR Pellets.
Therefore, the final dissolution method and acceptance criteria should always be established according to the specific finished-product specification.
Active loading is a key quality attribute for Ursodeoxycholic Acid IR Pellets. The intended concentration of UDCA should remain consistent throughout the manufactured pellet batch.
Content uniformity is particularly important for multiparticulate formulations because consistent distribution of the active ingredient helps support reproducible finished-product performance. Appropriate process controls and analytical testing can be used to evaluate active distribution and batch consistency.
The active ingredient specification should also be distinguished from the finished-pellet specification. API assay, moisture, impurity and other pharmacopoeial requirements should not automatically be transferred to the finished pellet.
High-quality Ursodeoxycholic Acid Pharmaceutical Pellets can be evaluated through chemical, physical and performance-related characteristics.
Chemical evaluation may include:
Physical evaluation may include:
Performance evaluation may include:
The final acceptance criteria should be based on the applicable finished-product specification.
Ursodeoxycholic Acid IR Pellets provide a flexible multiparticulate platform for immediate-release formulation development. Formulation developers can evaluate active loading, pellet size, core composition, excipient selection and physical characteristics according to the intended formulation.
Published UDCA pellet development work has demonstrated approaches including extrusion-spheronization, followed by drying and, where required, application of a functional or protective coating. Such formulation approaches illustrate the flexibility of UDCA multiparticulate technology, although the actual SDP manufacturing process and formulation should be based on the approved product specification.
The pellet format can also support process optimization and scale-up by providing defined physical characteristics for downstream manufacturing operations.
Ursodeoxycholic Acid IR Pellets from Swapnroop are positioned as pharmaceutical-grade multiparticulate pellets for immediate-release formulation and bulk pharmaceutical applications.
Key product advantages include:
As a Ursodeoxycholic Acid IR Pellets Manufacturer and Supplier in India, Swapnroop can position Ursodeoxycholic Acid immediate-release pellets for pharmaceutical formulation development, multiparticulate applications, capsule filling and bulk pharmaceutical requirements, subject to the applicable product specification.
The product can be developed around relevant formulation parameters including active loading, pellet size, physical characteristics, active distribution and immediate-release dissolution performance.
Customers searching for Ursodeoxycholic Acid IR Pellets Manufacturer in India, Ursodeoxycholic Acid IR Pellets Supplier in India, Ursodeoxycholic Acid 35% IR Pellets, Ursodeoxycholic Acid Pharmaceutical Pellets, Ursodeoxycholic Acid Immediate-Release Pellets, Ursodeoxycholic Acid Multiparticulate Pellets, and Ursodeoxycholic Acid Pellets for Capsule Filling can be naturally addressed through the product page's topical content.
Ursodeoxycholic Acid IR Pellets can be supplied in suitable pharmaceutical packaging according to the required:
Available Strength: As confirmed by the applicable SDP product specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |